Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combining estramustine and paclitaxel in
treating patients who have prostate cancer that has not responded to hormone therapy.
Phase:
Phase 1
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health